Update shared on23 Aug 2025
Fair value Decreased 6.58%The downward revision in Standard BioTools' analyst price target reflects declining net profit margin and a higher future P/E ratio, with the consensus fair value now lowered to $1.78.
What's in the News
- Standard BioTools announced a delay in filing their next 10-Q with the SEC.
- The company was dropped from multiple Russell growth indices, including Microcap, Small Cap, 2000, 2500, 3000, 3000E, and associated benchmark indices.
Valuation Changes
Summary of Valuation Changes for Standard BioTools
- The Consensus Analyst Price Target has fallen from $1.90 to $1.78.
- The Net Profit Margin for Standard BioTools has fallen from 14.18% to 12.80%.
- The Future P/E for Standard BioTools has risen slightly from 79.34x to 82.71x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.